Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD vs Capecitabine in Older Women with Metastatic Breast Cancer
NCT00082095Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Apr 2004
- Primary completion
- Dec 2005
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin in breast cancer, sponsored by Johnson & Johnson. Started Apr 2004; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00082095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082095.